Sym004 A novel investigational antibody mixture targeting the epidermal growth factor receptor (EGFR)
Sym008 Development and License Agreement
Global strategic collaboration for development of antibody therapeutics against three undisclosed infectious disease targets. Symphogen will apply its proprietary Symplex™antibody discovery technology platform to identify novel infectious disease drug candidates. Furthermore, Genentech will gain access to Symphogen’s Sympress™technology to produce recombinant polyclonal antibodies. Genentech has made an undisclosed upfront payment to Symphogen, as well as an equity investment in Symphogen. In addition, Symphogen is eligible to receive milestone payments upon the success of certain research and development milestones, as well as royalties on any products developed and commercialized by Genentech as a result of this collaboration. The total value of the agreement has the potential to exceed $ 330 million and Genentech will obtain an exclusive worldwide license to candidates developed through this agreement, and will fund associated research and development costs.
Meiji Holdings Co., Ltd.
Sym006 Development and License Agreement
Strategic collaboration for research, development and commercialization of a recombinant polyclonal antibody product candidate, against Pseudomonas aeruginosa infections, generated be the use of Symphogen's proprietary technologies for antibody discovery (Symplex™) and manufacturing (Sympress™). Symphogen received an initial technology access fee from Meiji and is eligible to receive development milestone payments as well as royalties on worldwide net sales from any successfully developed products. Meiji has agreed to fund the development costs associated with the program. Symphogen has retained certain co-development option rights in the United States and European Union. Financial terms not disclosed.